NEW YORK--(BUSINESS WIRE)--Celmatix, a personalized medicine company focused on fertility and women’s health, today announced it has named Dr. Erin Foran Wolff as its first Chief Medical Officer. In this position, Dr. Wolff will play an important role as the company prepares to launch its first genetic test and continues to scale its analytics platform, Polaris, already in use at leading fertility clinics across the US. In addition, Dr. Wolff will help support the ongoing clinical research efforts of the company.
Dr. Wolff comes to Celmatix from the National Institutes of Health in Washington, D.C., where she conducted basic, translational, and clinical reproductive research as an Assistant Clinical Investigator for the past five years. Dr. Wolff received her M.D. from Washington University School of Medicine in St. Louis, Missouri. After completing her residency training in Obstetrics and Gynecology at Yale-New Haven Hospital in New Haven, Connecticut, she became a Scholar of the Reproductive Scientist Development Program at Yale University School of Medicine. She then completed a fellowship in Reproductive Endocrinology and Infertility at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
“Dr. Wolff joins us at a key point in the growth of Celmatix,” explained Dr. Piraye Yurttas Beim, Celmatix Founder and CEO. “We are continuing to scale our clinical data network and product offerings through our Polaris platform and also accelerate our research and development pipeline. Dr. Wolff’s deep experience and expertise as an OB/GYN, reproductive endocrinology and infertility specialist, and NIH clinical investigator, will be a major asset to Celmatix.”
Dr. Wolff commented, “I’ve always felt a strong commitment to both patient care and research. My work at Celmatix will allow me to continue to move the needle in patient care, while also contributing to the ground-breaking research for which the company is known.” She continued, “This position gives me the unique opportunity to do both by developing better tools to provide care for women more effectively.”
Celmatix is a personalized medicine company that uses big data and predictive analytics to help individuals who are struggling to have a baby make informed decisions. Founded in 2009 and based in New York City, Celmatix is disrupting the way women approach their lifelong fertility journey by empowering them through science and technology. The company’s flagship product, Polaris, is in use at top fertility clinics across the country and is the world’s first analytics platform for optimizing fertility. Celmatix also has an active research and development program dedicated to decoding the genetic basis of fertility potential. For more information, visit www.celmatix.com.